Key result
Elevated serum TRAIL and lung MID1 proteins correlate with idiopathic pulmonary fibrosis and lower DLco.
Why the study?
TRAIL plays a pro-inflammatory role in allergic airways disease and COPD through MID1 upregulation and PP2A deactivation, but its role in pulmonary fibrosis was unclear.
Case-Control (n=16)
No
p-value: p=<0.05
TRAIL signalling through MID1 deactivates PP2A and promotes pulmonary fibrosis, suggesting MID1/PP2A as potential therapeutic targets for IPF.
Identifies the TRAIL/MID1 pathway as a potential therapeutic target in idiopathic pulmonary fibrosis.
Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL) has previously been demonstrated to play a pro-inflammatory role in allergic airways disease and COPD through the upregulation of the E3 ubiquitin ligase MID1 and the subsequent deactivation of protein phosphatase 2A (PP2A). Biopsies were taken from eight IPF patients presenting to the Second Affiliated Hospital of Jilin University, China between January 2013 and February 2014 with control samples obtained from resected lung cancers. Serum TRAIL, MID1 protein and PP2A activity in biopsies, and patients’ lung function were measured. Wild type and TRAIL deficient Tnfsf10 −/− BALB/c mice were administered bleomycin to induce fibrosis and some groups were treated with the FTY720 analogue AAL(s) to activate PP2A. Mouse fibroblasts were treated with recombinant TRAIL and fibrotic responses were assessed. TRAIL in serum and MID1 protein levels in biopsies from IPF patients were increased compared to controls. MID1 levels were inversely associated while PP2A activity levels correlated with DLco. Tnfsf10 −/− and mice treated with the PP2A activator AAL(s) were largely protected against bleomycin-induced reductions in lung function and fibrotic changes. Addition of recombinant TRAIL to mouse fibroblasts in-vitro increased collagen production which was reversed by PP2A activation with AAL(s). TRAIL signalling through MID1 deactivates PP2A and promotes fibrosis with corresponding lung function decline. This may provide novel therapeutic targets for IPF.
No takes yet. Share an insight, caveat, or question.
Collison et al. (2019) conducted a case-control in Idiopathic pulmonary fibrosis (n=16). Idiopathic pulmonary fibrosis vs. Control patients without fibrotic lung disease was evaluated on Serum TRAIL and lung biopsy MID1 protein levels (p=<0.05). Serum TRAIL and lung biopsy MID1 protein levels were significantly elevated in patients with idiopathic pulmonary fibrosis compared to controls, and MID1 levels inversely correlated with diffusing capacity of the lung for carbon monoxide.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: